1. Home
  2. TALK vs FHTX Comparison

TALK vs FHTX Comparison

Compare TALK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$3.96

Market Cap

442.1M

Sector

Health Care

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$6.67

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALK
FHTX
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
442.1M
360.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TALK
FHTX
Price
$3.96
$6.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$4.88
$11.43
AVG Volume (30 Days)
1.4M
190.1K
Earning Date
02-19-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$214,593,000.00
$24,518,000.00
Revenue This Year
$23.86
$40.89
Revenue Next Year
$22.22
$11.89
P/E Ratio
$157.53
N/A
Revenue Growth
18.37
N/A
52 Week Low
$2.22
$2.95
52 Week High
$4.36
$6.95

Technical Indicators

Market Signals
Indicator
TALK
FHTX
Relative Strength Index (RSI) 65.88 73.08
Support Level $3.45 $4.64
Resistance Level $4.14 $5.37
Average True Range (ATR) 0.15 0.41
MACD 0.03 0.11
Stochastic Oscillator 73.19 88.10

Price Performance

Historical Comparison
TALK
FHTX

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: